Pathogenic polyglutamine expansion length correlates with polarity of the flanking sequences

Molecular Neurodegeneration

Meewhi Kim¹ 

[1] Department of Physiology, UT Southwestern Medical Center, Dallas, TX 75390, USA

关键词: Ataxin;    Huntingtin;    Proteasome;    Primary sequence analysis;    Polyglutamine disorders;   

Others  :  1132683
DOI  :  10.1186/1750-1326-9-45

 received in 2014-06-13, accepted in 2014-10-23,  发布年份 2014

【 摘 要 】

Background

Polyglutamine (polyQ) repeat expansion within coding sequence of a soluble protein is responsible for eight autosomal-dominant genetic neurodegenerative disorders. These disorders affect cerebellum, striatum, basal ganglia and other brain regions. The pathogenic polyQ-expansion threshold in these proteins varies from 32Q to 54Q. Understanding the reasons for variability in pathogenic polyQ threshold may provide insights into pathogenic mechanisms responsible for development of these disorders.

Findings

Here we established a quantitative correlation between the polarity of the flanking sequences and pathogenic polyQ-expansion threshold in this protein family. We introduced an “edge polarity index” (^EPI) to quantify polarity effects of the flanking regions and established a strong correlation between ^EPI index and critical polyQ expansion length in this protein family. Based on this analysis we subdivided polyQ-expanded proteins into 2 groups – with strong and weak dependence of polyQ threshold on ^EPI index. The main difference between members of the first and the second group is a polarity profile of these proteins outside of polyQ and flanking regions. PolyQ proteins are known substrates for proteasome and most likely mechanistic explanation for the observed correlation is that proteasome may have an impaired ability to process continuous non-polar regions of proteins.

Conclusions

The proposed hypothesis provides a quantitative explanation for variability in pathogenic threshold among polyQ-expansion disorders, which we established to correlate with polarity of flanking regions. To explain these results we propose that proteasome is not efficient in processing continuous non-polar regions of proteins, resulting in release of undigested and partially digested fragments. If supported experimentally, our hypothesis may have wide implications for further understanding the pathogensis of polyglutamine expansion disorders.

【 授权许可】

   
2014 Kim; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Gusella JF, MacDonald ME: Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 2000, 1:109-115.
• [2]Havel LS, Li S, Li XJ: Nuclear accumulation of polyglutamine disease proteins and neuropathology. Mol Brain 2009, 2:21. BioMed Central Full Text
• [3]Banfi S, Chung MY, Kwiatkowski TJ Jr, Ranum LP, McCall AE, Chinault AC, Orr HT, Zoghbi HY: Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb. Genomics 1993, 18:627-635.
• [4]Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, Sahba S: Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996, 14:269-276.
• [5]Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, Kimura J, Narumiya S, Kakizuka A: CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994, 8:221-228.
• [6]Toru S, Murakoshi T, Ishikawa K, Saegusa H, Fujigasaki H, Uchihara T, Nagayama S, Osanai M, Mizusawa H, Tanabe T: Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function. J Biol Chem 2000, 275:10893-10898.
• [7]David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel JL, Brice A: Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997, 17:65-70.
• [8]Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I: SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001, 10:1441-1448.
• [9]Tobin AJ, Signer ER: Huntington's disease: the challenge for cell biologists. Trends Cell Biol 2000, 10:531-536.
• [10]Ross CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
• [11]Rubinsztein DC: Lessons from animal models of Huntington's disease. Trends Genet 2002, 18:202-209.
• [12]Li SH, Li XJ: Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004, 20:146-154.
• [13]Bezprozvanny I: Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009, 15:89-100.
• [14]Cha JH: Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007, 83:228-248.
• [15]Truant R, Atwal RS, Desmond C, Munsie L, Tran T: Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J 2008, 275:4252-4262.
• [16]Takahashi T, Katada S, Onodera O: Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? J Mol Cell Biol 2010, 2:180-191.
• [17]Pennuto M, Palazzolo I, Poletti A: Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum Mol Genet 2009, 18:R40-R47.
• [18]Zimmerman JM, Eliezer N, Simha R: The characterization of amino acid sequences in proteins by statistical methods. J Theor Biol 1968, 21:170-201.
• [19]Gasteiger EHC, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A: Protein identification and analysis tools on the ExPASy server. In The Proteomics Protocols Handbook. Edited by John M, Walker JM. New York City, USA: Humana Press; 2005:571-607.
• [20]Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I: Secondary structure of Huntingtin amino-terminal region. Structure 2009, 17:1205-1212.
• [21]Kim M: Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues. Prion 2013, 7:221-228.
• [22]Raspe M, Gillis J, Krol H, Krom S, Bosch K, van Veen H, Reits E: Mimicking proteasomal release of polyglutamine peptides initiates aggregation and toxicity. J Cell Sci 2009, 122:3262-3271.
• [23]Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI: Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 2004, 23:4307-4318.
• [24]Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL: Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004, 14:95-104.
• [25]Jana NR, Zemskov EA, Wang G, Nukina N: Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001, 10:1049-1059.
• [26]Ghoda L, van Daalen Wetters T, Macrae M, Ascherman D, Coffino P: Prevention of rapid intracellular degradation of ODC by a carboxyl-terminal truncation. Science 1989, 243:1493-1495.
• [27]Blake NW, Moghaddam A, Rao P, Kaur A, Glickman R, Cho YG, Marchini A, Haigh T, Johnson RP, Rickinson AB, Wang F: Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J Virol 1999, 73:7381-7389.
• [28]Lin L, Ghosh S: A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 1996, 16:2248-2254.
• [29]Hoyt MA, Zich J, Takeuchi J, Zhang M, Govaerts C, Coffino P: Glycine-alanine repeats impair proper substrate unfolding by the proteasome. EMBO J 2006, 25:1720-1729.
• [30]Tian L, Holmgren RA, Matouschek A: A conserved processing mechanism regulates the activity of transcription factors Cubitus interruptus and NF-kappaB. Nat Struct Mol Biol 2005, 12:1045-1053.
• [31]DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
• [32]Haacke A, Broadley SA, Boteva R, Tzvetkov N, Hartl FU, Breuer P: Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum Mol Genet 2006, 15:555-568.
• [33]Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP: Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 2010, 285:8808-8823.
• [34]Young JE, Gouw L, Propp S, Sopher BL, Taylor J, Lin A, Hermel E, Logvinova A, Chen SF, Chen S, Bredesen DE, Truant R, Ptacek LJ, La Spada AR, Ellerby LM: Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem 2007, 282:30150-30160.
• [35]Suzuki Y, Nakayama K, Hashimoto N, Yazawa I: Proteolytic processing regulates pathological accumulation in dentatorubral-pallidoluysian atrophy. FEBS J 2010, 277:4873-4887.
• [36]Verhoef LG, Lindsten K, Masucci MG, Dantuma NP: Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 2002, 11:2689-2700.
• [37]Beitel LK, Elhaji YA, Lumbroso R, Wing SS, Panet-Raymond V, Gottlieb B, Pinsky L, Trifiro MA: Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J Mol Endocrinol 2002, 29:41-60.
• [38]Poukka H, Karvonen U, Janne OA, Palvimo JJ: Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A 2000, 97:14145-14150.
• [39]Burnett B, Li F, Pittman RN: The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 2003, 12:3195-3205.
• [40]Kuhlbrodt K, Janiesch PC, Kevei E, Segref A, Barikbin R, Hoppe T: The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol 2011, 13:273-281.
• [41]Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR: Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 1996, 271:19385-19394.
• [42]Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL: SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
• [43]Ansorge O, Giunti P, Michalik A, Van Broeckhoven C, Harding B, Wood N, Scaravilli F: Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats. Ann Neurol 2004, 56:448-452.
• [44]Matilla A, Gorbea C, Einum DD, Townsend J, Michalik A, van Broeckhoven C, Jensen CC, Murphy KJ, Ptacek LJ, Fu YH: Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex. Hum Mol Genet 2001, 10:2821-2831.
• [45]Ferrell K, Wilkinson CR, Dubiel W, Gordon C: Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem Sci 2000, 25:83-88.
• [46]Chew BS, Siew WL, Xiao B, Lehming N: Transcriptional activation requires protection of the TATA-binding protein Tbp1 by the ubiquitin-specific protease Ubp3. Biochem J 2010, 431:391-399.
• [47]Trachtulec Z, Hamvas RM, Forejt J, Lehrach HR, Vincek V, Klein J: Linkage of TATA-binding protein and proteasome subunit C5 genes in mice and humans reveals synteny conserved between mammals and invertebrates. Genomics 1997, 44:1-7.
• [48]Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, Perez AM, Branco J, de Haro M, Patterson C, Zoghbi HY, Botas J: CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 2006, 281:26714-26724.
• [49]Choi JY, Ryu JH, Kim HS, Park SG, Bae KH, Kang S, Myung PK, Cho S, Park BC, do Lee H: Co-chaperone CHIP promotes aggregation of ataxin-1. Mol Cell Neurosci 2007, 34:69-79.
• [50]Matsuyama Z, Izumi Y, Kameyama M, Kawakami H, Nakamura S: The effect of CAT trinucleotide interruptions on the age at onset of spinocerebellar ataxia type 1 (SCA1). J Med Genet 1999, 36:546-548.
• [51]Jayaraman M, Kodali R, Wetzel R: The impact of ataxin-1-like histidine insertions on polyglutamine aggregation. Protein Eng Des Sel 2009, 22:469-478.
• [52]Sharma D, Sharma S, Pasha S, Brahmachari SK: Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions. FEBS Lett 1999, 456:181-185.
• [53]Sen S, Dash D, Pasha S, Brahmachari SK: Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: a molecular approach. Protein Sci 2003, 12:953-962.